Home » Newsletters » BioWorld Science

BioWorld Science

March 31, 2009

View Archived Issues

Clinical studies reveal efficacy of bepotastine in treating allergic conjunctivitis

Fourth quarter highlights at Merck KGaA

Novel substituted tetrahydronaphthalines claimed by sanofi-aventis

Novel b-Raf inhibitors claimed by Takeda

Agile signs clinical trial agreement for its progestin-only contraceptive patch AG-1000

FDA issues complete response letter to Dyax regarding BLA for DX-88 in HAE

Biogen Idec reports favorable interim results from phase IIa studies of BIIB-014 in PD

Infinity initiates phase II IPI-504 trial in HER2-positive breast cancer

Faron presents update on its lead compoumd Traumakine

FDA clears Curemark's IND for phase III clinical trial of CM-AT in autism

reMYND presents first-in-class drug candidates for Alzheimer's, Parkinson's disease

Oral MC-4 receptor antagonists developed by Santhera for cachexia

Novel compounds for the treatment of mood disorders presented by GlaxoSmithKline

Boehringer Ingelheim claims the discovery of novel arylsulfonamides with analgesic activity

Novel phosphodiesterase type 10 inhibitors claimed by Amgen

Portola Pharmaceuticals describes second-generation P2Y12 inhibitors

Dual specificity antibody displays in vitro and in vivo antiproliferative activity

Tadalafil improves benign prostatic hyperplasia symptoms regardless of erectile function status

Archemix initiates phase IIa ARC-1779 trial

EffRx signs expansion of licensing deal with Nycomed for EX-101

AstraZeneca to meet with FDA Psychopharmacologic Drugs Advisory Committee

Seattle Genetics receives FDA fast track for SGN-35 for Hodgkin's lymphoma

Arena reports pivotal phase III results for lorcaserin in obesity

PharmaMar and Taiho sign license agreement for antitumor drug Yondelis in Japan

Ixiaro vaccine receives FDA approval for Japanese encephalitis prevention

FDA approves Afinitor in patients with advanced kidney cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...